Catalog No.
DHJ05602
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Leukocyte-associated immunoglobulin-like receptor 1, LAIR-1, hLAIR1, LAIR1, CD305
Concentration
0.83 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q6GTX8
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IO-106, IO 106, IO106
Clone ID
IO 106
CD305 participates in abnormal activation of memory CD4+ T cells in patients with RA and attenuates collagen-induced arthritis., PMID:39079337
Utility of leukocyte-associated immunoglobulin-like receptor-1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B-cell non-Hodgkin lymphoma., PMID:39031805
Efficient delivery of the lncRNA LEF1-AS1 through the antibody LAIR-1 (CD305)-modified Zn-Adenine targets articular inflammation to enhance the treatment of rheumatoid arthritis., PMID:38062469
1,25-Dihydroxyvitamin D3 and 20-Hydroxyvitamin D3 Upregulate LAIR-1 and Attenuate Collagen Induced Arthritis., PMID:34948139
A non-stimulatory monoclonal antibody against the inhibitory immunoreceptor LAIR-1., PMID:24694245
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia., PMID:24415628
Development and evaluation of a sandwich ELISA method for the detection of human CD306., PMID:23954474
Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection., PMID:21763239
CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection., PMID:21482706
Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010., PMID:20951742
Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry., PMID:20951740
Analysis of HLDA9 mAbs on plasmacytoid dendritic cells., PMID:20933012
Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation., PMID:20923684
[Comparison of the binding affinity of LAIR-1(CD305) and LAIR-2(CD306) with their ligands]., PMID:17908491
Natalizumab therapy for moderate to severe Crohn disease in adolescents., PMID:17255829
Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies., PMID:16918507
The Eighth Human Leucocyte Differentiation Antigen (HLDA8) Workshop: natural killer cell section report., PMID:16157321
[The proliferation, phenotype change and anti-tumor activity of cytokine induced killer cells]., PMID:16143062
[Identification of cell lines expressing the putative ligand(s) for LAIR-1(CD305) and LAIR-2(CD306)]., PMID:16143055
For research use only. Not for human or drug use.
